journal article·2024-09Open access

Dual electro-/pH-responsive nanoparticle/hydrogel system for controlled delivery of anticancer peptide

Leonor Resina, Teresa Esteves, Sílvia Pérez-Rafael, José Ignacio Hernández García, Frederico Castelo Ferreira, Tzanko Tzanov, Sebastian Bonardd, David Díaz Díaz, Maria M. Pérez-Madrigal, Carlos Alemán

Abstract

An electro-chemo-responsive carrier has been engineered for the controlled release of a highly hydrophilic anticancer peptide, CR(NMe)EKA (Cys-Arg- N-methyl-Glu-Lys-Ala). Remotely controlled on demand release of CR(NMe)EKA, loaded in electro-responsive poly(3,4-ethylenedioxythiophene) (PEDOT) nanoparticles, has been achieved by applying electrical stimuli consisting of constant positive (+0.50 V) or negative voltages (-0.50 V) at pre-defined time intervals. In addition, after loading CR(NMe)EKA/PEDOT nanoparticles into an injectable pH responsive hydrogel formed by phenylboronic acid grafted to chitosan (PBA-CS), the efficiency of the controlled peptide release has increased approximately by a factor of 2.6. The hydration ratio of such hydrogel is significantly lower in acidic environments than in neutral and basic media, which has been attributed to the dissociation of the boronate bonds between polymer chains. Hence, the electro-controlled peptide release from PBA-CS/CR(NMe)EKA/PEDOT hydrogels, in the acidic environment of tumors, combines the effects of the oxidation and reduction of PEDOT chains on the interactions with the peptide and the carrier, with the peptide concentration gradient at the interface between the collapsed hydrogel and the release medium. Furthermore, the peptide released by electro-stimulation preserved its bioactivity assessed by promoting human prostate cancer cells death. Overall, this work is a promising attempt to develop a carrier platform for small hydrophilic anticancer peptides, which delivery rationale is synergistically regulated by the electrical and pH responsiveness of the carrier.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Graphene and Nanomaterials Applications · Advanced Sensor and Energy Harvesting Materials · Electrospun Nanofibers in Biomedical Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (62)

Show source-provided references
1. Therapeutic peptides: current applications and future directions10.1038/s41392-022-00904-4 ↗
2. Modified natriuretic peptides and their potential roles in cancer treatment
3. Peptides as a platform for targeted therapeutics for cancer: peptide–drug conjugates (PDCs)10.1039/D0CS00556H ↗
4. Antimicrobial peptides as therapeutic agents: opportunities and challenges10.1080/07388551.2020.1796576 ↗
5. Comprehensive review on current advances in peptide drug development and design10.3390/ijms20102383 ↗
6. Peptide-based therapeutics: quality specifications, regulatory considerations, and prospects10.1016/j.drudis.2018.10.002 ↗
7. The future of peptide-based drugs10.1111/cbdd.12055 ↗
8. Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum10.1371/journal.pone.0178943 ↗
9. On the utility of chemical strategies to improve peptide gut stability10.1021/acs.jmedchem.2c00094 ↗
10. Therapeutic application of peptides and proteins: parenteral forever?10.1016/j.tibtech.2009.07.009 ↗
11. Peptide therapeutics: current status and future directions10.1016/j.drudis.2014.10.003 ↗
12. Factors affecting the physical stability (aggregation) of peptide therapeutics10.1098/rsfs.2017.0030 ↗
13. Strategies to improve plasma half life time of peptide and protein drugs10.1007/s00726-005-0289-3 ↗
14. Therapeutic peptides: historical perspectives, current development trends, and future directions10.1016/j.bmc.2017.06.052 ↗
15. Peptidomimetic toolbox for drug discovery10.1039/D0CS00102C ↗
16. Trends in peptide drug discovery10.1038/s41573-020-00135-8 ↗
17. Chemically modified and conjugated antimicrobial peptides against superbugs10.1039/D0CS01026J ↗
18. Structure by design: from single proteins and their building blocks to nanostructures10.1016/j.tibtech.2006.08.004 ↗
19. Oral delivery of therapeutic peptides and proteins: technology landscape of lipid-based nanocarriers
20. Particle carriers for controlled release of peptides10.1016/j.jconrel.2023.03.050 ↗
21. Design of polymeric carriers for intracellular peptide delivery in oncology applications10.1021/acs.chemrev.0c00963 ↗
22. Challenges in delivering therapeutic peptides and proteins: a silk-based solution10.1016/j.jconrel.2022.02.011 ↗
23. Nanoparticle-induced vascular blockade in human prostate cancer10.1182/blood-2010-03-274258 ↗
24. Fibrin-targeting peptide CREKA-conjugated multi-walled carbon nanotubes for self-amplified photothermal therapy of tumor10.1016/j.biomaterials.2015.11.061 ↗
25. Fibrin-binding, peptide amphiphile micelles for targeting glioblastoma10.1016/j.biomaterials.2013.10.064 ↗
26. Fibrin association at hybrid biointerfaces made of clot-binding peptides and polythiophene10.1002/mabi.201600128 ↗
27. Polyethylene glycol–polylactic acid nanoparticles modified with cysteine–arginine–glutamic acid–lysine–alanine fibrin-homing peptide for glioblastoma therapy by enhanced retention effect
28. CREKA peptide-conjugated dendrimer nanoparticles for glioblastoma multiforme delivery10.1016/j.jcis.2015.03.019 ↗
29. Encapsulation and storage of therapeutic fibrin-homing peptides using conducting polymer nanoparticles for programmed release by electrical stimulation10.1021/acsbiomaterials.9b01794 ↗
30. Low-intensity focused ultrasound-responsive phase-transitional nanoparticles for thrombolysis without vascular damage: a synergistic nonpharmaceutical strategy10.1021/acsnano.8b09277 ↗
31. One-pot synthesis of nanochain particles for targeting brain tumors10.1039/C7NR02370G ↗
32. Incorporation of a clot-binding peptide into polythiophene: properties of composites for biomedical applications10.1021/am503904h ↗
33. Fibrin association at hybrid biointerfaces made of clot-binding peptides and polythiophene10.1002/mabi.201600128 ↗
34. Enhanced antitumor and anti-metastasis efficacy against aggressive breast cancer with a fibronectin-targeting liposomal doxorubicin10.1016/j.jconrel.2017.12.026 ↗
35. Engineering strategy to improve peptide analogs: from structure-based computational design to tumor homing10.1007/s10822-012-9623-5 ↗
36. Aggregation propensity of therapeutic fibrin-homing pentapeptides: insights from experiments and molecular dynamics simulations10.1039/D0SM00930J ↗
37. Dendritic self-assembled structures from therapeutic charged pentapeptides10.1021/acs.langmuir.2c02010 ↗
38. Phenylboronic acid grafted chitosan as a glucose-sensitive vehicle for controlled insulin release10.1002/jps.22463 ↗
39. Liang, pH and glucose dually responsive injectable hydrogel prepared by in situ crosslinking of phenylboronic modified chitosan and oxidized dextran. J. Polym. Sci. Part a10.1002/pola.27556 ↗
40. Electrostimulated release of neutral drugs from polythiophene nanoparticles: smart regulation of drug–polymer interactions10.1002/adhm.201700453 ↗
41. Conducting polymer nanoparticles for a voltage-controlled release of pharmacological chaperones10.1039/D1SM00036E ↗
42. Multilayer hydrophilic poly(phenol-formaldehyde resin)-coated magnetic graphene for boronic acid immobilization as a novel matrix for glycoproteome analysis10.1021/acsami.5b04295 ↗
43. The infrared absorption of amino acid side chains10.1016/S0079-6107(00)00021-3 ↗
44. Comparison of different characterization methods for nanoparticle dispersions before and after aerosolization10.1039/C4AY01203H ↗
45. Solid lipid nanoparticles for parenteral drug delivery10.1016/j.addr.2003.12.002 ↗
46. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide10.1016/S0378-5173(99)00412-3 ↗
47. Advanced functional hydrogel biomaterials based on dynamic b–o bonds and polysaccharide building blocks10.1021/acs.biomac.0c01139 ↗
48. Boronic acid-modified alginate enables direct formation of injectable, self-healing and multistimuli-responsive hydrogels10.1039/C7CC00765E ↗
49. The pK(a) values of acidic and basic residues buried at the same internal location in a protein are governed by different factors10.1016/j.jmb.2009.03.039 ↗
50. The role of hydrophobic microenvironments in modulating pKa shifts in proteins10.1002/prot.10153 ↗
51. Drug delivery systems based on intrinsically conducting polymers10.1016/j.jconrel.2019.07.035 ↗
52. Battery-free and wireless smart wound dressing for wound infection monitoring and electrically controlled on-demand drug delivery10.1002/adfm.202100852 ↗
53. Combining rapid and sustained insulin release from conducting hydrogels for glycemic control10.1016/j.eurpolymj.2022.111670 ↗
54. Nanotheranostic interface based on antibiotic-loaded conducting polymer nanoparticles for real-time monitoring of bacterial growth inhibition10.1002/adhm.202001636 ↗
55. Discrimination between the human prostate normal and cancer cell exometabolome by GC-MS10.1038/s41598-018-23847-9 ↗
56. The pH of prostatic fluid: a reappraisal and therapeutic implications10.1016/S0022-5347(17)57333-4 ↗
57. Why do cancers have high aerobic glycolysis?10.1038/nrc1478 ↗
58. The acidic tumor microenvironment as a driver of cancer10.1146/annurev-physiol-021119-034627 ↗
59. The acidic tumor microenvironment: a target for smart cancer nano-theranostics10.1093/nsr/nwx062 ↗
60. Electroresponsive alginate-based hydrogels for controlled release of hydrophobic drugs10.1021/acsbiomaterials.0c01400 ↗
61. Boron-containing acids: preliminary evaluation of acute toxicity and access to the brain determined by Raman scattering spectroscopy10.1016/j.neuro.2013.10.005 ↗
62. Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein–mediated drug resistance10.1158/1535-7163.MCT-10-0884 ↗